A comprehensive view of vaccination/immunization. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Catalent and Moderna to extend, expand manufacturing partnership; Catalent to continue Moderna COVID-19 programs, may extend partnership for flu, RSV vaccines, starting at Bloomington, Indiana, facility then expanding to Anagni, Italy, plant
Published: February 07, 2023 by Outsourcing-Pharma.com
Commentary: Drug companies that made billions from pandemic could see those sales fall by two-thirds globally in 2023 due to built-up product inventories; population immunity from vaccination, past infections means demand for treatments could dip as well
Published: February 06, 2023 by Financial Express (India)
Moderna signs new agreement to use the Personalis NeXT Platform in clinical studies of mRNA-4157/V940, a personalized cancer vaccine jointly developed with Merck; platform will sequence patient genomic information to identify unique genetic mutations
Published: February 06, 2023 by ENP Newswire
Executive Perspective: Pfizer CEO states 2023 pipeline may have the largest number of new product and indication launches they’ve ever had; Pfizer expects to introduce 19 new products or indications to the market in next 18 months
Published: February 06, 2023 by Outsourcing-Pharma.com
FDA to convene advisors to review experimental RSV vaccine candidate from Pfizer on February 28; group to meet in March to reviews RSV vaccine candidate from GSK
Published: February 03, 2023 by BioPharma Dive

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count